CTI Biopharma Corp reports results for the quarter ended in September - Earnings Summary

CTI Biopharma

20/11/2021 08:28

* CTI Biopharma Corp  CTIC.OQ  reported a quarterly adjusted
loss of 26 cents​​ per share for the quarter ended in September.
The mean expectation of six analysts for the quarter was for a
loss of 25 cents per share.
* Reported revenue was zero​;  analysts expected zero. 
* CTI Biopharma Corp's reported EPS for the quarter was a loss
of 26 cents​.
* The mean earnings estimate of analysts had fallen by
about 0.7% in the last three months.​ 
* In the last 30 days there have been no earnings estimate
revisions by analysts covering the company. 
* CTI Biopharma Corp shares had fallen by 18.0% this quarter and
lost 24.8% so far this year.
* The company reported a quarterly loss of $24.18 million.
* Wall Street's median 12-month price target for CTI Biopharma
Corp is $6.10 
* The current average analyst rating on the shares is "buy" and
the breakdown of recommendations is 6 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell." 
This summary was machine generated November 20 at 08:28 a.m.
 ​All figures in US dollars unless otherwise stated